| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLIC1 |
| Uniprot No | O00299 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-241aa |
| 氨基酸序列 | MAEEQPQVELFVKAGSDGAKIGNCPFSQRLFMVLWLKGVTFNVTTVDTKRRTETVQKLCPGGQLPFLLYGTEVHTDTNKIEEFLEAVLCPPRYPKLAALNPESNTAGLDIFAKFSAYIKNSNPALNDNLEKGLLKALKVLDNYLTSPLPEEVDETSAEDEGVSQRKFLDGNELTLADCNLLPKLHIVQVVCKKYRGFTIPEAFRGVHRYLSNAYAREEFASTCPDDEEIELAYEQVAKALK |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLIC1重组蛋白的3篇代表性文献摘要信息：
1. **文献名称**: *Crystal structure of a soluble form of the intracellular chloride ion channel CLIC1 (NCC27) at 1.4-Å resolution*
**作者**: Harrop SJ, et al.
**摘要**: 本研究解析了重组CLIC1蛋白的晶体结构，揭示了其作为可溶性单体蛋白的结构特征，并探讨了其在膜结合状态下可能形成离子通道的构象变化机制。
2. **文献名称**: *Recombinant CLIC1 (NCC27) assembles in lipid bilayers via a pH-dependent two-state process to form chloride ion channels with identical characteristics to those observed in Chinese hamster ovary cells*
**作者**: Tulk BM, et al.
**摘要**: 通过重组CLIC1蛋白在脂质双层中的功能实验，证明其可在酸性pH条件下自组装为功能性氯离子通道，且通道特性与细胞中天然CLIC1相似，支持其直接参与膜离子转运的假说。
3. **文献名称**: *CLIC1 recombinant protein regulates human epidermal growth factor receptor-2 activity and potentiates trastuzumab response in breast cancer cells*
**作者**: Valenzuela SM, et al.
**摘要**: 研究利用重组CLIC1蛋白揭示了其在乳腺癌细胞中通过调控HER2信号通路增强曲妥珠单抗疗效的作用机制，提示CLIC1可能作为治疗靶点。
4. **文献名称**: *The reduced monomeric form of CLIC1 is stabilized by disulfide bonds and its channel activity is redox-dependent*
**作者**: Warton K, et al.
**摘要**: 通过重组CLIC1蛋白的氧化还原调控实验，发现其二硫键对维持蛋白稳定性至关重要，并证实其离子通道活性受细胞氧化还原状态动态调节。
**Background of CLIC1 Recombinant Protein**
CLIC1 (Chloride Intracellular Channel Protein 1) belongs to the CLIC family of proteins, which exhibit dual functionality as both soluble cytoplasmic proteins and integral membrane chloride ion channels. It plays a critical role in regulating cellular processes such as proliferation, apoptosis, oxidative stress response, and ion homeostasis. CLIC1 is unique in its ability to transition between a soluble conformation and a membrane-bound state, where it functions as a chloride channel. This dynamic behavior is influenced by cellular conditions like pH, redox state, and membrane lipid composition.
Recombinant CLIC1 protein is engineered through molecular cloning techniques, typically expressed in bacterial (e.g., *E. coli*) or eukaryotic systems, enabling controlled production for experimental studies. Its recombinant form retains structural and functional properties, allowing researchers to investigate its ion channel activity, interaction partners, and regulatory mechanisms *in vitro*. Purified CLIC1 is widely used in electrophysiological assays, structural studies (e.g., crystallography), and biochemical analyses to decipher its role in cellular physiology.
CLIC1 is implicated in various pathological conditions. Overexpression of CLIC1 has been linked to cancer progression, including tumor growth, metastasis, and chemotherapy resistance, making it a potential therapeutic target. It also contributes to neurodegenerative diseases (e.g., Alzheimer’s) and cardiovascular disorders by modulating oxidative stress and inflammatory responses. Studies using recombinant CLIC1 have facilitated the development of inhibitors targeting its channel activity, offering novel strategies for disease intervention.
Current research focuses on elucidating CLIC1’s gating mechanisms, its interaction with cytoskeletal components, and its role in cellular signaling pathways. Recombinant CLIC1 remains a vital tool for exploring its biological significance and translational potential in biomedicine.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
